Research programme: immune checkpoint inhibitors - Innate Pharma/OREGA Biotech

Drug Profile

Research programme: immune checkpoint inhibitors - Innate Pharma/OREGA Biotech

Alternative Names: anti-huCD39 mAb; IPH-52

Latest Information Update: 25 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator INSERM; Orega Biotech
  • Developer Innate Pharma
  • Class Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Adenosine triphosphatase inhibitors; Checkpoint kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 19 Apr 2016 Pharmacodynamics data from a preclinical trial in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 10 Jan 2016 Preclinical trials in Cancer in France (unspecified route) before January 2016
  • 10 Jan 2016 Innate Pharma in-licenses immune checkpoint inhibitor technology from OREGA Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top